PKMYT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dasatinib Anhydrous (SCHEMBL8226)	1.00	3/20
Dasatinib Anhydrous (SCHEMBL290515)	1.00	3/20
SCHEMBL1147156	0.84	3/20
SCHEMBL1147171	0.84	3/20
SCHEMBL1146489	0.81	3/20
SCHEMBL1146496	0.81	3/20
SCHEMBL1147074	0.80	3/20
SCHEMBL1147022	0.79	3/20
SCHEMBL1147135	0.79	3/20
SCHEMBL1147166	0.79	3/20
SCHEMBL773489	0.78	3/20
SCHEMBL793206	0.77	3/20
SCHEMBL1146862	0.77	3/20
SCHEMBL1146991	0.77	3/20
SCHEMBL1147072	0.77	3/20
SCHEMBL793188	0.76	3/20
SCHEMBL792953	0.74	3/20
SCHEMBL1147089	0.74	3/20
SCHEMBL1146450	0.57	3/20
SCHEMBL1147178	0.56	3/20

Clinical trials — most relevant to PKMYT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Prevention of Renal Complications of Diabetes With Thiamine	PHASE4	UNKNOWN
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes	PHASE2	RECRUITING
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas	PHASE1	COMPLETED
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Human Requirements for the Nutrient Choline	nan	COMPLETED
Intermittent Fasting for Pancreatitis	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Immune Cell Response to Stimuli	nan	RECRUITING
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC	nan	UNKNOWN
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PKMYT1 binder may also engage these)

Protein	Name	Similarity
Q9ESG9	—	0.999	Q9ESG9 →
Q8N1F8	—	0.957	Q8N1F8 →
Q96JH8	—	0.956	Q96JH8 →
Q69Z89	—	0.955	Q69Z89 →
Q02833	—	0.954	Q02833 →
Q9DD19	—	0.954	Q9DD19 →
Q86UR1	—	0.952	Q86UR1 →
Q6GQT6	—	0.951	Q6GQT6 →
PML	Protein PML	0.951	landscape →
Q8N9H8	—	0.949	Q8N9H8 →
A2RRU4	—	0.948	A2RRU4 →
A6QM06	—	0.948	A6QM06 →
Q9QXW0	—	0.947	Q9QXW0 →
P41155	—	0.947	P41155 →
Q96G42	—	0.947	Q96G42 →
Q5MNU5	—	0.946	Q5MNU5 →
Q70EL4	—	0.946	Q70EL4 →
Q12770	—	0.945	Q12770 →
Q32PI0	—	0.945	Q32PI0 →
P97260	—	0.945	P97260 →
SHARPIN	Sharpin (Shank-associated RH domain-interacti	0.945	landscape →
PKN1	Serine/threonine-protein kinase N1	0.945	landscape →
Q8N531	—	0.945	Q8N531 →
Q9JM10	—	0.944	Q9JM10 →
Q5RF19	—	0.944	Q5RF19 →
Q01113	—	0.944	Q01113 →
Q9DCF1	—	0.944	Q9DCF1 →
E7ERA6	—	0.944	E7ERA6 →
Q8IW40	—	0.944	Q8IW40 →
O94827	—	0.942	O94827 →